AIMS: Both elevated inflammatory activity and sustained tachycardia reflect unfavourable cardiovascular risk profiles, and there is evidence to suggest the deleterious effects of inflammation are amplified by increased heart rate. The purpose of this study was to assess the interaction between resting heart rate and inflammation in cardiovascular mortality. METHODS AND RESULTS: A total of 3267 patients (2283 men), aged 18-95 years, scheduled for coronary angiography, were followed prospectively. By principle component analysis, we developed an overall multi-marker index of inflammation weighting the respective coefficients of five inflammatory markers including: interleukin-6, C-reactive protein, serum amyloid A, neutrophils, and fibrinogen. Cox proportional hazard regression models were employed to evaluate the relationship between inflammation and heart rate with cardiovascular mortality. Across 29,940 person years of follow-up, there were 546 (17%) deaths due to cardiovascular disease (CVD). Significantly, we observed a strong synergistic effect of inflammatory activity and concurrent elevated heart rate. For CVD mortality, patients in the highest quartile of inflammation had an adjusted hazard ratio (95% confidence interval) of 1.84 (1.31-2.57), P < 0.0001 if their resting heart rate was <75 b.p.m. Substantially, patients had a greater adjusted HR of 7.50 (3.21-17.50), P < 0.0001 if their resting heart rate was ≥75 b.p.m. CONCLUSION: The present analyses underline elevated inflammation as a risk factor for cardiovascular mortality. The effects of inflammation appeared to be strongly amplified by a faster resting heart rate. If confirmed by additional studies, this association may prove a useful adjunct for therapeutic approaches to alleviate symptoms and prolong survival.
AIMS: Both elevated inflammatory activity and sustained tachycardia reflect unfavourable cardiovascular risk profiles, and there is evidence to suggest the deleterious effects of inflammation are amplified by increased heart rate. The purpose of this study was to assess the interaction between resting heart rate and inflammation in cardiovascular mortality. METHODS AND RESULTS: A total of 3267 patients (2283 men), aged 18-95 years, scheduled for coronary angiography, were followed prospectively. By principle component analysis, we developed an overall multi-marker index of inflammation weighting the respective coefficients of five inflammatory markers including: interleukin-6, C-reactive protein, serum amyloid A, neutrophils, and fibrinogen. Cox proportional hazard regression models were employed to evaluate the relationship between inflammation and heart rate with cardiovascular mortality. Across 29,940 person years of follow-up, there were 546 (17%) deaths due to cardiovascular disease (CVD). Significantly, we observed a strong synergistic effect of inflammatory activity and concurrent elevated heart rate. For CVD mortality, patients in the highest quartile of inflammation had an adjusted hazard ratio (95% confidence interval) of 1.84 (1.31-2.57), P < 0.0001 if their resting heart rate was <75 b.p.m. Substantially, patients had a greater adjusted HR of 7.50 (3.21-17.50), P < 0.0001 if their resting heart rate was ≥75 b.p.m. CONCLUSION: The present analyses underline elevated inflammation as a risk factor for cardiovascular mortality. The effects of inflammation appeared to be strongly amplified by a faster resting heart rate. If confirmed by additional studies, this association may prove a useful adjunct for therapeutic approaches to alleviate symptoms and prolong survival.
Authors: Bríain O'Hartaigh; Marco Pahor; Thomas W Buford; John A Dodson; Daniel E Forman; Thomas M Gill Journal: Am Heart J Date: 2014-07-30 Impact factor: 4.749
Authors: Bert N Uchino; Joshua Landvatter; Sierra Cronan; Emily Scott; Michael Papadakis; Timothy W Smith; Jos A Bosch; Samantha Joel Journal: Psychosom Med Date: 2019-05 Impact factor: 4.312
Authors: Bríain ó Hartaigh; Heather G Allore; Mark Trentalange; Gail McAvay; Stefan Pilz; John A Dodson; Thomas M Gill Journal: Eur J Prev Cardiol Date: 2014-01-20 Impact factor: 7.804
Authors: Seamus P Whelton; Venkata Narla; Michael J Blaha; Khurram Nasir; Roger S Blumenthal; Nancy S Jenny; Mouaz H Al-Mallah; Erin D Michos Journal: Am J Cardiol Date: 2013-11-23 Impact factor: 2.778
Authors: Pierre-Jean Saulnier; Brad P Dieter; Stephanie K Tanamas; Sterling M McPherson; Kevin M Wheelock; William C Knowler; Helen C Looker; Rick L Meek; Robert G Nelson; Katherine R Tuttle Journal: Am J Nephrol Date: 2017-09-22 Impact factor: 3.754
Authors: Bert N Uchino; Robert G Kent de Grey; Sierra Cronan; Timothy W Smith; Ed Diener; Samantha Joel; Jos Bosch Journal: J Behav Med Date: 2017-09-07